815630-99-0Relevant articles and documents
Development of a control strategy for a defluorinated analogue in the manufacturing process of casopitant mesylate
Bravo, Fernando,Cimarosti, Zadeo,Tinazzi, Francesco,Castoldi, Damiano,Stonestreet, Paul,Galgano, Annalisa,Westerduin, Pieter
, p. 832 - 839 (2010)
Casopitant mesylate was identified as part of the search for drugs with activity on the Central Nervous System (CNS) by GlaxoSmithKline. During late-phase development studies to develop the manufacturing process, a new impurity was found. This synthetic i
NK1 ANTAGONIST
-
Page/Page column 98, (2010/02/09)
The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-meditated conditions.Formula (I)